This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
O Agid , S Kapur , T Arenovich , RB Zipursky (2003). Delayed-onset hypothesis of antipsychotic action – a hypothesis tested and rejected. Archives of General Psychiatry 60, 1228–1235.
O Agid , S Kapur , L Warrington , A Loebel , (2008). Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophrenia Research 102, 241–248.
S Akhondzadeh , M Tabatbaee , H Amini , SA Ahmadi Abhari , (2007). Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophrenia Research 90, 179–185.
A Aleman , IE Sommer , RS Kahn (2007). Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. Journal of Clinical Psychiatry 68, 416–421.
J Alexander , P Tharyan , C Adams , T John , (2004). Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting – pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. British Journal of Psychiatry 185, 63–69.
AC Altamura , I Velona , R Curreli , E Mundo , (2002). Is olanzapine better than haloperidol in resistant schizophrenia? A double-blind study in partial responders. International Journal of Psychiatry in Clinical Practice 6, 107–111.
NC Andreasen , M Pressler , P Nopoulos , D Miller , (2010). Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biological Psychiatry 67, 255–262.
M Arato , R O'Connor , H Meltzer , Zeus study group (2002). Ziprasidone in the long-term treatment of negative symptoms and the prevention of exacerbation of schizophrenia. International Clinical Psychopharmacology 17, 207–215.
H Ascher-Svanum , AW Nyhuis , DE Faries , BJ Kinon , (2008). Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophrenia Bulletin 34, 1163–1171.
RJ Baldessarini , BM Cohen , MH Teicher (1988). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry 45, 79–91.
C Barbui , B Saraceno , A Liberati , S Garattini (1996). Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials. European Psychiatry 11, 306–311.
C Barbui , A Signoretti , S Mule , M Boso , (2009). Does the addition of a second antipsychotic drug improve Clozapine treatment? Schizophrenia Bulletin 35, 458–468.
TR Barnes , MA McPhillips (1995). How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. International Clinical Psychopharmacology 10 (Suppl. 3), 115–121.
A Basan , W Kissling , S Leucht (2004). Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophrenia Research 70, 33–37.
J Battaglia , S Moss , J Rush , J Kang , (1997). Haloperidol, lorazepam, or both for psychotic agitation: a multicenter, prospective, double blind, emergency department study. American Journal of Emergency Medicine 15, 335–340.
P Baumann , C Hiemke , S Ulrich , G Eckermann , (2004). The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37, 243–265.
P Bollini (1994). Antipsychotic drugs: is more worse? A meta analysis of the published randomized controlled trials. Psychological Medicine 24, 307–316.
A Breier , SH Hamilton (1999). Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biological Psychiatry 45, 403–411.
RW Buchanan , MP Ball , E Weiner , B Kirkpatrick , (2005). Olanzapine treatment of residual positive and negative symptoms. American Journal of Psychiatry 162, 124–129.
RW Buchanan , J Kreyenbuhl , DL Kelly , JM Noel , (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 36, 71–93.
C Bushe , M Shaw , RC Peveler (2008). A review of the association between antipsychotic use and hyperprolactinaemia. Journal of Psychopharmacology 22, 46–55.
WT Carpenter , TE Hanlon , DW Heinrichs , AT Summerfelt , (1990). Continuous vs. targeted medication in schizophrenic outpatients: outcome results. American Journal of Psychiatry 147, 1138–1163.
DE Casey , DG Daniel , C Tamminga , JM Kane , (2009). Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 34, 1330–1338.
DE Casey , DG Daniel , AA Wassef , KA Tracy , (2003). Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28, 182–192.
M Chakos , J Lieberman , E Hoffman , D Bradford , (2001). Effectiveness of second generation antipsychotics for treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 158, 518–526.
JS Chang , YM Ahn , HJ Park , KY Lee , (2008). Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 69, 720–731.
YC Chang , HY Lane , KH Yang , CL Huang (2006). Optimizing early prediction for antipsychotic response in schizophrenia. Journal of Clinical Psychopharmacology 26, 554–559.
EYH Chen , CLM Hui , MML Lam , CPY Chiu , (2010). Maintenance treatment with quetiapine vs. discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. British Medical Journal 341, c4024.
HK Cheung (1981). Schizophrenics fully remitted on neuroleptics for 3–5 years–to stop or continue drugs? British Journal of Psychiatry 138, 490–494.
WL Chua , AD Santiago , J Kulkarni , A Mortimer (2005). Estrogen for schizophrenia. Cochrane Database of Systematic Reviews. Issue 4, Art No. CD004719.
L Citrome (2007). Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. Journal of Clinical Psychiatry 68, 1876–1885.
RR Conley , DL Kelly , MW Nelson , CM Richardson , (2005). Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clinical Neuropharmacology 28, 163–168.
RR Conley , CA Tamminga , JJ Bartko , C Richardson , (1998). Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. American Journal of Psychiatry 155, 914–920.
CU Correll , S Leucht , JM Kane (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies. American Journal of Psychiatry 161, 414–415.
CU Correll , AK Malhotra , S Kaushik , (2003). Early prediction of antipsychotic response in schizophrenia. American Journal of Psychiatry 160, 2063–2065.
CU Correll , C Rummel-Kluge , C Corves , JM Kane , (2009). Antipsychotic combinations vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin 35, 443–457.
CU Correll , EM Schenk (2008). Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry 21, 151–156.
TJ Crow , JF MacMillan , AL Johnson , EC Johnstone (1986). A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 148, 120–127.
JM Davis , N Chen (2004). Dose-response and dose equivalence of antipsychotics. Journal of Clinical Psychopharmacology 24, 192–208.
JM Davis (1974). Dose equivalence of the antipsychotic drugs. Journal of Psychiatric Research 11, 65–69.
JM Davis , N Chen , ID Glick (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60, 553–564.
M De Hert , JM Dekker , D Wood , KG Kahl , (2009). Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry 24, 412–424.
H Ehrenreich , D Hinze-Selch , S Stawicki , C Aust , (2007). Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Molecular Psychiatry 12, 206–220.
A Elias , A Kumar (2007). Testosterone for schizophrenia. Database of Systematic Reviews. Issue 3. Art. No. CD006197.
RA Emsley , J Raniwalla , PJ Bailey , AM Jones (2000). A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. International Clinical Psychopharmacology 15, 121–131.
A Essali , HN Al-Haj , C Li , J Rathbone (2009). Clozapine vs. typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews. Issue 1. Art. No. CD000059.
P Falkai , T Wobrock , J Lieberman , B Glenthoj , (2005). World Federation of Societies of Biological Psychiatry (WFSBP) – Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry 6, 132–191.
WW Fleischhacker , ME Heikkinen , JP Olie , W Landsberg , (2008). Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. European Psychiatry 23, S114–S115.
W Gaebel , AG Awad (1994). Prediction of Neuroleptic Treatment Outcome in Schizophrenia. Concepts and Methods. Wien: Springer Verlag.
W Gaebel , M Riesbeck , W Wölwer , AW Klimke , (2010). Relapse prevention in first episode schizophrenia. Maintenance vs. intermittent drug treatment with a prodrome based early intervention: Results of a randomised controlled trial within the German research network on schizophrenia. Journal of Clinical Psychiatry. Published online: 29 June 2010. doi:10.4088/JCP.09m05459yel.
W Gaebel , S Weinmann , N Sartorius , W Rutz , (2005). Schizophrenia practice guidelines: international survey and comparison. British Journal of Psychiatry 187, 248–255.
DM Gardner , AL Murphy , H O'Donnell , F Centorrino , (2010). International consensus study of antipsychotic dosing. American Journal of Psychiatry 167, 686–693.
J Geddes , N Freemantle , P Harrison , P Bebbington (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321, 1371–1376.
P Gilbert , J Harris , LA McAdams , DV Jeste (1995). Neuroleptic withdrawal in schizophrenia. Review of the literature . Archives of General Psychiatry 52, 173–188.
G Goodwin , W Fleischhacker , C Arango , P Baumann , (2009). Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. European Neuropsychopharmacology 19, 520–532.
J Hamann , S Leucht , W Kissling (2003). Shared decision making in psychiatry. Acta Psychiatrica Scandinavica 107, 403–409.
B Hartung , M Wada , G Laux , S Leucht (2005). Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews. Issue 1. Art. No. CD003443.
MI Herz , WM Glazer , MA Mostert , MA Sheard , (1991). Intermittent vs. maintenance medication in schizophrenia. Two-year results. Archives of General Psychiatry 48, 333–339.
GE Hogarty , JP McEvoy (1988). Dose of fluphenazine, familial expressed emotions and outcome in schizophrenia. Archives of General Psychiatry 45, 797–805.
GE Hogarty , RF Ulrich (1998). The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. Journal of Psychiatric Research 32, 243–250.
OJ Hoyberg , C Fensbo (1993). Risperidone vs. perphenazine in the treatment of chronic schizophrenic patients with acute exacerbation. Acta Psychiatrica Scandinavica 88, 396–402.
G Huf , ES Coutinho , CE Adams (2007). Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol vs. intramuscular haloperidol plus promethazine. British Medical Journal 335, 869.
G Huf , ESF Coutinho , CE Adams , RVS Borges , (2003). Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam vs. haloperidol plus promethazine. British Medical Journal 327, 708–711.
M Jager , M Schmauss , G Laux , H Pfeiffer , (2009). Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study 3. European Psychiatry 24, 501–506.
DV Jeste , JP Lacro , PL Gilbert , J Kline , (1993). Treatment of late-life schizophrenia with neuroleptics. Schizophrenia Bulletin 19, 817–830.
DA Johnson , JM Ludlow , K Street , RD Taylor (1987). Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. British Journal of Psychiatry 151, 634–638.
DAW Johnson (1979). Further observation on the duration of depot neuroleptic maintenance therapy in schizophrenia. British Journal of Psychiatry 135, 524–530.
AG Jolley , SR Hirsch (1990). Trial brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. 540British Medical Journal 301, 837–842.
PB Jones , TRE Barnes , L Davies , G Dunn , (2006). Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia – cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry 63, 1079–1086.
RS Kahn , WW Fleischhacker , H Boter , M Davidson , (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085–1097.
JM Kane (1982). Fluphenazine vs. placebo in patients with remitted, acute first-episode schizophrenia. Archives of General Psychiatry 39, 70–73.
JM Kane , CU Correll , DC Goff , B Kirkpatrick , (2009). A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. Journal of Clinical Psychiatry 70, 1348–1357.
JM Kane , JM Davis , N Schooler , S Marder , (2002). A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. American Journal of Psychiatry 159, 554–560.
JM Kane , G Honigfeld , J Singer , H Meltzer , (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789–796.
JM Kane , S Khanna , S Rajadhyaksha , E Giller (2006). Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. International Clinical Psychopharmacology 21, 21–28.
JM Kane , SR Marder , NR Schooler , WC Wirshing , (2001). Clozapine and haloperidol in moderately refractory schizophrenia – a 6-month randomized and double-blind comparison. Archives of General Psychiatry 58, 965–972.
JM Kane , HY Meltzer , WH Carson , RD McQuade , (2007). Aripiprazole for treatment-resistant schizophrenia: Results of a multicenter, randomized, double-blind, comparison study vs. perphenazine. Journal of Clinical Psychiatry 68, 213–223.
JM Kane , A Rifkin , M Woerner , G Reardon , (1983). Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates . Archives of General Psychiatry 40, 893–896.
S Kapur , T Arenovich , O Agid , R Zipursky , (2005). Evidence for onset of antipsychotic effects within the first 24 h of treatment. American Journal of Psychiatry 162, 939–946.
BJ Kinon , L Chen , H Ascher-Svanum , VL Stauffer , (2008 a). Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research 102, 230–240.
BJ Kinon , L Chen , H Ascher-Svanum , VL Stauffer , (2010). Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 35, 581–590.
BJ Kinon , J Volavka , V Stauffer , SE Edwards , (2008 b). Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. Journal of Clinical Psychopharmacology 28, 392–400.
W Kissling , JM Kane , TR Barnes , K Dencker , (1991). Guidelines for neuroleptic relapse prevention in schizophrenia: towards consensus view. In: W Kissling (Ed.), Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (pp. 155–163). Heidelberg, Berlin: Springer.
E Klein , Y Kolsky , M Puyerovsky , D Koren , (1999). Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double-blind sham-controlled pilot study. Biological Psychiatry 46, 1451–1454.
MI Krakowski , P Czobor , L Citrome , N Bark , TB Cooper (2006). Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 63, 622–629.
DL Kleinberg , JM Davis , R de Coster , B Van Baelen , (1999). Prolactin levels and adverse events in patients treated with risperidone. Journal of Clinical Psychopharmacology 19, 57–61.
M Lambert , BG Schimmelmann , D Naber , FX Eich , (2009). Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry 42, 277–283.
C Leucht , M Kitzmantel , L Chua , J Kane , (2008 a). Haloperidol vs. chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews. Issue 1. Art. No. CD004278.
S Leucht , TRE Barnes , W Kissling , RR Engel , (2003 a). Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry 160, 1209–1222.
S Leucht , R Busch , J Hamann , W Kissling , (2005 a). Early onset of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological Psychiatry 57, 1543–1549.
S Leucht , R Busch , W Kissling , JM Kane (2007 a). Early prediction of antipsychotic non-response. Journal of Clinical Psychiatry 68, 352–360.
S Leucht , C Corves , D Arbter , RR Engel , (2009 a). Second-generation vs. first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31–41.
S Leucht , JM Kane , E Etschel , W Kissling , (2006). Linking the PANSS, BPRS, and CGI: Clinical implications. Neuropsychopharmacology 31, 2318–2325.
S Leucht , JM Kane , W Kissling , J Hamann , (2005 b). Clinical implications of BPRS scores. British Journal of Psychiatry 187, 363–371.
S Leucht , JM Kane , W Kissling , J Hamann , (2005 c). What does the PANSS mean? Schizophrenia Research 79, 231–238.
S Leucht , W Kissling , J McGrath (2007 b). Lithium for schizophrenia. Cochrane Database of Systematic Reviews. Issue 3. Art. No. CD003834.
S Leucht , K Komossa , C Rummel-Kluge , C Corves , (2009 b). A meta-analysis of head to head comparisons of second generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 166, 152–163.
S Leucht , J McGrath , P White , W Kissling (2002 a). Carbamazepine augmentation for schizophrenia: how good is the evidence? Journal of Clinical Psychiatry 63, 218–224.
S Leucht , G Pitschel-Walz , R Engel , W Kissling (2002 b). Amisulpride – an unusual atypical antipsychotic. A meta-analysis of randomized controlled trials. American Journal of Psychiatry 159, 180–190.
S Leucht , AS Shamsi , R Busch , W Kissling , (2008 c). Early prediction of antipsychotic response – replication and six weeks extension. Schizophrenia Research 101, 312–319.
S Leucht , K Wahlbeck , J Hamann , W Kissling (2003 b). New generation antipsychotics vs. low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361, 1581–1589.
SZ Levine , S Leucht (2010). Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biological Psychiatry 68, 86–92.
SW Lewis , TR Barnes , L Davies , RM Murray , (2006). Randomized controlled trial of effect of prescription of clozapine vs. other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32, 715–723.
JA Lieberman , TS Stroup , JP McEvoy , MS Swartz , (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209–1223.
JA Lieberman (1998). Maximizing clozapine therapy: managing side effects. Journal of Clinical Psychiatry 59, 38–43.
CH Lin , LS Chou , CH Lin , CY Hsu , (2007). Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. Journal of Clinical Psychiatry 68, 1522–1527.
JP Lindenmayer , A Khan , A Iskander , MT Abad , (2007). A randomized controlled trial of olanzapine vs. haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. Journal of Clinical Psychiatry 68, 368–379.
SR Marder , T Vanputten , J Mintz , J McKenzie , (1984). Costs and benefits of 2 doses of fluphenazine. Archives of General Psychiatry 41, 1025–1029.
JP McEvoy , GE Hogarty , S Steingard (1991). Optimal dose of neuroleptic in acute schizophrenia. Archives of General Psychiatry 48, 740–745.
JP McEvoy , JA Lieberman , TS Stroup , SM Davis , (2006). Effectiveness of clozapine vs. olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163, 600–610.
N Muller , M Riedel , C Scheppach , B Brandstatter , (2002). Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry 159, 1029–1034.
D Naber , H Hippius (1990). The European experience with use of clozapine. Hospital and Community Psychiatry 41, 886–890.
JW Newcomer (2005). Second-generation (atypical) antipsychotics and metabolic effects – a comprehensive literature review. CNS Drugs 19, 1–93.
S Nolte , D Wong , G Latchford (2004). Amphetamines for schizophrenia. Cochrane Database of Systematic Reviews. Issue 4. Art No. CD004964.
OA Odejide , AF Aderounmu (1982). Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Journal of Clinical Psychiatry 43, 195–196.
IM Omori , J Wang (2009). Sulpiride vs. placebo for schizophrenia. Cochrane Database of Systematic Reviews. Issue 2. Art. No. CD007811.
C Paton , C Whittington , TR Barnes (2007). Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine – a meta-analysis. Journal of Clinical Psychopharmacology 27, 198–204.
A Pietzcker , W Gaebel , W Koepcke , M Linden , (1993). Intermittent vs. maintenance neuroleptic long-term treatment in schizophrenia – 2 years results of a german multicenter study. Journal of Psychiatric Research 27, 321–339.
TS Premkumar , J Pick (2006). Lamotrigine for schizophrenia. Cochrane Database of Systematic Reviews. Issue 4. Art No. CD005962.
NS Raveendran , P Tharyan , J Alexander , CE Adams (2007). Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine vs. intramuscular haloperidol plus promethazine. British Medical Journal 335, 865.
D Robinson , MG Woerner , JM Alvir , R Bilder , (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 56, 241–247.
R Rosenheck , J Cramer , WC Xu , J Thomas , (1997). A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 337, 809–815.
R Rosenheck , D Perlick , S Bingham , W Liu-Mares , (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia – a randomized controlled trial. Journal of the American Medical Association 290, 2693–2702.
C Rummel , W Kissling , S Leucht (2006). Antidepressants for the negative symptoms of schizophrenia. Cochrane Database of Systematic Reviews. Issue 3. Art No. CD005581.
C Rummel-Kluge , K Komossa , S Schwarz , H Hunger , (2010). Second generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophrenia Bulletin. Published online: 31 May 2010. doi:10.1093/schbul/sbq042.
G Sampath , A Shah , J Krska , SD Soni (1992). Neuroleptic discontinuation in the very stable schizophrenic patient – relapse rates and serum neuroleptic levels. Human Psychopharmacology: Clinical and Experimental 7, 255–264.
NR Schooler , SJ Keith , JB Severe , SM Matthews , (1997). Relapse and rehospitalization during maintenance treatment of schizophrenia. Archives of General Psychiatry 54, 453–463.
RE See , AA Fido , M Maurice , MM Ibrahim , (1999). Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia. Biological Psychiatry 45, 1653–1656.
AA Sepehry , S Potvin , R Elie , E Stip (2007). Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. Journal of Clinical Psychiatry 68, 604–610.
A Shalev , H Hermesh , J Rothberg , H Munitz (1993). Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica 87, 86–91.
GM Simpson , RA Mahmoud , RA Lasser , M Kujawa , (2006). A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry 67, 1194–1203.
SP Singh , V Singh , N Kar , K Chan (2010). Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. British Journal of Psychiatry 197, 174–179.
SG Siris (1991). Diagnosis of secondary depression in schizophrenia: Implications for DSM-IV. Schizophrenia Bulletin 17, 75–98.
RC Smith , M Infante , A Singh , A Khandat (2001). The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. International Journal of Neuropsychopharmacology 4, 239–250.
E Stip , AA Sepehry , S Chouinard (2007). Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2. Clinical Neuropharmacology 30, 218–229.
JM Stone , M Raffin , P Morrison , PK McGuire (2010). The biological basis of antipsychotic response in schizophrenia. Journal of Psychopharmacology 24, 953–964.
TS Stroup , JA Lieberman , JP McEvoy , MS Swartz , (2007). Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. American Journal of Psychiatry 164, 415–427.
T Suzuki , H Uchida , K Watanabe , K Nomura , (2007). How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone? – a randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology (Berlin) 195, 285–295.
DM Taylor , L Smith (2009). Augmentation of clozapine with a second antipsychotic – a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatrica Scandinavica 119, 419–425.
P Tharyan , CE Adams (2005). Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews Issue 2. Art No. CD000076.
J Tiihonen , K Wahlbeck , V Kiviniemi (2009). The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 109, 10–14.
TA Trikalinos , R Churchill , M Ferri , S Leucht , (2004). Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. Journal of Clinical Epidemiology 57, 1124–1130.
J Volavka , P Czobor , B Sheitman , JP Lindenmayer , (2002). Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. American Journal of Psychiatry 159, 255–262.
K Wahlbeck , M Cheine , A Essali , C Adams (1999). Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. American Journal of Psychiatry 156, 990–999.
CY Wang , YT Xiang , ZJ Cai , YZ Weng , (2010). Risperidone maintenance treatment in schizophrenia. A randomised, controlled trial. American Journal of Psychiatry 167, 676–685.
P Waraich , C Adams , K Hammill , J Marti , (2002). Haloperidol dose for the acutely ill phase of schizophrenia. Cochrane Database of Systematic Reviews. Issue 2, Art. No. CD001951.
C Whitehead , S Moss , A Cardno , G Lewis (2003). Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychological Medicine 33, 589–599.
L Wunderink , FJ Nienhuis , S Sytema , CJ Slooff , (2007). Guided discontinuation vs. maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. Journal of Clinical Psychiatry 68, 654–661.
DL Zimbroff , JM Kane , CA Tamminga , DG Daniel , (1997). Controlled, dose response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry 154, 782–791.